
MAZE Stock Forecast & Price Target
MAZE Analyst Ratings
Bulls say
Maze Therapeutics Inc is strategically advancing its pipeline with two promising precision medicine programs, MZE829 and MZE782, targeting chronic kidney disease through its innovative Compass platform. Recent Phase 1 results for MZE782 demonstrated substantial pharmacodynamic activity, including a 42-fold increase in urinary phenylalanine without evidence of tubular injury, thus bolstering confidence in its therapeutic potential and safety profile. Furthermore, the compound's compelling efficacy data suggests that it may serve as a competitive hemodynamic modulator in the treatment landscape, particularly in chronic kidney disease, positioning the company for significant market share opportunities.
Bears say
Maze Therapeutics Inc's stock outlook is negatively impacted by multiple systemic safety liabilities that could constrain the effectiveness of its therapies, specifically those targeting chronic kidney disease. The company's two primary programs, MZE782 and MZE829, face significant risks including potential failures in clinical studies, challenges in securing regulatory approval in major markets, and difficulties in achieving projected peak commercial revenues due to market size and pricing issues. Collectively, these factors contribute to uncertainty in the company's ability to deliver on investor expectations and create a viable path to profitability.
This aggregate rating is based on analysts' research of Maze Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MAZE Analyst Forecast & Price Prediction
Start investing in MAZE
Order type
Buy in
Order amount
Est. shares
0 shares